KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Average (2016 - 2025)

Historic Equity Average for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to $1.8 billion.

  • CRISPR Therapeutics AG's Equity Average fell 748.61% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 748.61%. This contributed to the annual value of $1.9 billion for FY2024, which is 150.6% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Equity Average of $1.8 billion as of Q3 2025, which was down 748.61% from $1.8 billion recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Equity Average high stood at $2.6 billion for Q3 2021, and its period low was $1.7 billion during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $1.9 billion (2024), whereas its average is $2.0 billion.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Equity Average soared by 14540.15% in 2021, and later plummeted by 2204.53% in 2022.
  • CRISPR Therapeutics AG's Equity Average (Quarter) stood at $2.5 billion in 2021, then fell by 22.05% to $1.9 billion in 2022, then decreased by 5.71% to $1.8 billion in 2023, then rose by 7.23% to $1.9 billion in 2024, then decreased by 6.32% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q3 2025, $1.8 billion for Q2 2025, and $1.9 billion during Q1 2025.